The results of the<unk> <unk><unk>  were recently presented in AHA 2011 held at Orlando, Florida. The<unk>  hypothesis was that raising HDL cholesterol by adding Niaspan (extended release<unk>  to simvastatin would provide an additional 25% reduction in cardiovascular events in patients with established cardiovascular disease and well-controlled LDL cholesterol levels. However, an early termination of the<unk>  was done as an interim analysis found that combination therapy do not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol. The inclusion criteria was very tight (small % of<unk> -risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the<unk>  should not be applied beyond the patient population<unk> ed.
Niacin AIM HIGH study
Diabetes mellitus type 2 Cost-Effectiveness of Therapy
GRACE
Dietary inflammatory index
Hypercholesterolemia NCEP ATP III guidelines
MAYO risk score
Low density lipoprotein classification
High density lipoprotein classification